New drug crizanlizumab tested for safety in indian sickle cell patients
NCT ID NCT04662931
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the safety of a drug called crizanlizumab in 140 Indian patients aged 16 and older with sickle cell disease who have had painful crises. The drug was given by IV infusion over several months, with or without standard hydroxyurea therapy. The main goal was to check for serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
crizanlizumab (a drug given by IV infusion to reduce painful crises)
What this could lead to
If successful, this could confirm that crizanlizumab is safe for Indian patients with sickle cell disease, potentially reducing their painful crises.
What could go wrong
This is a completed Phase IV safety study, not designed to prove how well the drug works. Side effects or lack of benefit in this specific population are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE (SCD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Guwahati, Assam, 781003, India
-
Novartis Investigative Site
Raipur, Chhattisgarh, 492099, India
-
Novartis Investigative Site
Kozhikode, Kerala, 673008, India
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751003, India
-
Novartis Investigative Site
Hyderabad, Telangana, 500082, India
-
Novartis Investigative Site
Lucknow, Uttar Pradesh, 226014, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700014, India